JP2015502340A5 - - Google Patents

Download PDF

Info

Publication number
JP2015502340A5
JP2015502340A5 JP2014539044A JP2014539044A JP2015502340A5 JP 2015502340 A5 JP2015502340 A5 JP 2015502340A5 JP 2014539044 A JP2014539044 A JP 2014539044A JP 2014539044 A JP2014539044 A JP 2014539044A JP 2015502340 A5 JP2015502340 A5 JP 2015502340A5
Authority
JP
Japan
Prior art keywords
seq
antibody
variable region
chain variable
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014539044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502340A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/062124 external-priority patent/WO2013063395A1/en
Publication of JP2015502340A publication Critical patent/JP2015502340A/ja
Publication of JP2015502340A5 publication Critical patent/JP2015502340A5/ja
Pending legal-status Critical Current

Links

JP2014539044A 2011-10-27 2012-10-26 iNKTに対するヒト化抗体 Pending JP2015502340A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552337P 2011-10-27 2011-10-27
US61/552,337 2011-10-27
PCT/US2012/062124 WO2013063395A1 (en) 2011-10-27 2012-10-26 Humanized antibodies to inkt

Publications (2)

Publication Number Publication Date
JP2015502340A JP2015502340A (ja) 2015-01-22
JP2015502340A5 true JP2015502340A5 (enExample) 2015-12-17

Family

ID=48168549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014539044A Pending JP2015502340A (ja) 2011-10-27 2012-10-26 iNKTに対するヒト化抗体

Country Status (13)

Country Link
US (1) US9932402B2 (enExample)
EP (1) EP2755688A4 (enExample)
JP (1) JP2015502340A (enExample)
KR (1) KR20140093964A (enExample)
CN (1) CN103945867B (enExample)
AU (1) AU2012328588C1 (enExample)
BR (1) BR112014009962A2 (enExample)
CA (1) CA2853719A1 (enExample)
HK (2) HK1199837A1 (enExample)
IL (1) IL232017A0 (enExample)
RU (1) RU2014120694A (enExample)
SG (1) SG11201401319XA (enExample)
WO (1) WO2013063395A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271629A1 (en) * 2013-03-14 2014-09-18 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
US20150165021A1 (en) * 2013-11-05 2015-06-18 Nkt Therapeutics Inc. Combination therapy
RU2693084C2 (ru) * 2014-01-10 2019-07-01 Анаптисбайо, Инк. Антитела, направленные против интерлейкина-33 (il-33)
WO2015121393A1 (en) * 2014-02-14 2015-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease
TW202136296A (zh) * 2014-06-27 2021-10-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
EP3190415B1 (en) 2014-07-25 2019-05-01 Riken Memory invariant nkt cell marker
WO2016018850A1 (en) * 2014-07-28 2016-02-04 Nkt Therapeutics Inc. Combination therapy with il-12
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
CN109152798B (zh) * 2015-12-02 2022-10-21 斯特库比股份有限公司 特异于糖基化的pd-1的抗体及其使用方法
KR20180130541A (ko) 2016-03-29 2018-12-07 주식회사 에스티큐브앤컴퍼니 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법
WO2017176651A1 (en) 2016-04-04 2017-10-12 True North Therapeutics, Inc. Anti-complement factor bb antibodies and uses thereof
KR20190031299A (ko) 2016-07-20 2019-03-25 주식회사 에스티큐브 글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법
SMT202500445T1 (it) * 2016-09-16 2026-01-12 Shanghai Henlius Biotech Inc Anticorpi anti-pd-1 per l'uso nel trattamento del cancro
KR20210121136A (ko) * 2019-01-29 2021-10-07 상하이 지아오통 유니버시티 키메라 항원 수용체 및 그 용용
PH12022552558A1 (en) * 2020-04-20 2024-04-22 Genzyme Corp Humanized anti-complement factor bb antibodies and uses thereof
JP2023522979A (ja) * 2020-04-23 2023-06-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア iNKT細胞の活性化による老化細胞の排除
MX2023010240A (es) 2021-03-01 2023-11-24 Deciduous Therapeutics Inc Compuestos para activar células t asesinas naturales invariantes y métodos de uso en la eliminación de células senescentes inflamatorias.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
WO1997016203A1 (en) 1995-11-01 1997-05-09 Genetics Institute, Inc. Methods for administration of il-12
AU2087799A (en) 1997-12-31 1999-07-19 Brigham And Women's Hospital Diagnostic and therapeutic methods based upon valpha24jalphaq t cells
DK1297017T3 (da) * 2000-06-19 2012-09-17 Dana Farber Cancer Inst Inc Sammensætninger og fremgangsmåder med monoklonale og polyklonale antistoffer, der er specifikke for T-cellesubpopulationer
NZ530582A (en) 2001-07-17 2008-06-30 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins, including granzyme, bax and TNF
EP1552462B1 (en) 2002-06-14 2011-03-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods of treating and preventing colitis involving il-13 and nk-t cells
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
KR101377116B1 (ko) * 2004-08-27 2014-03-24 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 면역 및 자가면역의 조절제로서의 세라마이드 유도체
WO2006060117A2 (en) * 2004-11-02 2006-06-08 The Board Of Trustees Of The Leland Stanford Junior University Methods for inhibition of nkt cells
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008140487A2 (en) 2006-11-14 2008-11-20 Elusys Therapeutics, Inc. Improved staphylococcal protein a mono- and bispecific antibodies and methods of their use
WO2008100912A1 (en) * 2007-02-12 2008-08-21 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
US8012484B2 (en) * 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity
US20090028849A1 (en) * 2007-07-24 2009-01-29 O'brien Rebecca L Agents and methods for inhibition of airway hyperresponsiveness
WO2009026412A1 (en) 2007-08-21 2009-02-26 Children's Medical Center Corporation Treatment of airway hyperreactivity
EP2222700A2 (en) 2007-11-27 2010-09-01 Medtronic, Inc. Humanized anti-amyloid beta antibodies
GB0902916D0 (en) 2009-02-20 2009-04-08 Fusion Antibodies Ltd Antibody therapy
CA2792754C (en) 2010-03-12 2019-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services .beta.-mannosylceramide and stimulation of nkt cell anti-tumor immunity
WO2011149881A2 (en) 2010-05-24 2011-12-01 Children's Medical Center Corporation Methods for the treatment and prevention of inflammatory diseases
US9365496B2 (en) 2011-11-30 2016-06-14 Ludwig Institute For Cancer Research iNKT cell modulators and methods of using the same
US20150165021A1 (en) 2013-11-05 2015-06-18 Nkt Therapeutics Inc. Combination therapy
WO2016018850A1 (en) 2014-07-28 2016-02-04 Nkt Therapeutics Inc. Combination therapy with il-12

Similar Documents

Publication Publication Date Title
RU2014120694A (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К iNKT
CN113710229B (zh) 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
IL274595B2 (en) Antibodies specific to beta-tgf
JP2014526898A5 (enExample)
JP2013538057A5 (enExample)
JP2016509009A5 (enExample)
JP2018512138A5 (enExample)
JP2012525829A5 (enExample)
JP2017504577A5 (enExample)
JP2012501669A5 (enExample)
FI2897981T3 (fi) Anti-CD3-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:ta, ja niiden käyttöjä
RU2018112861A (ru) Стабильные антитела, связывающиеся с несколькими антигенами
JP2015511962A5 (enExample)
JP2014509510A5 (enExample)
TR201817932T4 (en) ANTIBODIES THAT BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN SPECIFICALLY AND METHODS OF USE
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2012254092A5 (enExample)
JP2018515474A5 (enExample)
JP2017505125A5 (enExample)
JP2014502955A5 (enExample)
JP2018510617A5 (enExample)
JP2017531427A5 (enExample)
JP2015514110A5 (enExample)
JP2014110810A5 (enExample)
JP2012501670A5 (enExample)